Das Produkt wurde korrekt in den Warenkorb gelegt.

discount label
H-R^MFPNAPYL-OH
3D-Ansicht

Biosynth logo

H-R^MFPNAPYL-OH

Ref. 3D-PP49836

Unbestimmte GrößeNachfragen
Voraussichtliche Lieferung in Vereinigte Staaten, am Dienstag 10. Dezember 2024

Produktinformation

Name:
H-R^MFPNAPYL-OH
Beschreibung:

Peptide H-R^MFPNAPYL-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-R^MFPNAPYL-OH include the following: The antitumor activity of TCR-mimic antibody-drug conjugates (TCRm-ADCs) targeting the intracellular wilms tumor 1 (WT1) oncoprotein Y Shen, YM Li, JJ Zhou, Z Zhou , YC Xu - International Journal of , 2019 - mdpi.comhttps://www.mdpi.com/1422-0067/20/16/3912 An In Vivo Screen to Identify Short Peptide Mimotopes with Enhanced Antitumor Immunogenicity X He , S Zhou , B Quinn, D Jahagirdar , J Ortega - Cancer immunology , 2022 - AACRhttps://aacrjournals.org/cancerimmunolres/article-abstract/10/3/314/681732 Understanding CD8+ T-cell responses toward the native and alternate HLA-A∗02:01-restricted WT1 epitope THO Nguyen , ACL Tan, SD Xiang - Clinical & , 2017 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1038/cti.2017.4 Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine T Shirakawa , K Kitagawa - Human Vaccines & Immunotherapeutics, 2018 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/21645515.2017.1382787 An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A* 02: 01 and HLA-A* 24: 02 molecules T Dao, T Korontsvit, V Zakhaleva, C Jarvis - , 2017 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/2162402X.2016.1252895 A TCR mimic monoclonal antibody for the HPV-16 E7-epitope p11-19/HLA-A* 02: 01 complex T Dao, S Mun, T Korontsvit, AG Khan, MA Pohl, T White - Plos one, 2022 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0265534 A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML T Dao, G Xiong, SS Mun, J Meyerberg, T Korontsvit - Blood, 2024 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/143/6/507/506498 Prospective identification of cross-reactive human peptide-MHC ligands for T cell receptor based therapies RS Gejman , MG Klatt , A Chang , HF Jones, CY Oh - BioRxiv, 2018 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/267047.abstract Identification of the targets of T-cell receptor therapeutic agents and cells by use of a high-throughput genetic platform RS Gejman , HF Jones, MG Klatt , AY Chang - Cancer immunology , 2020 - AACRhttps://aacrjournals.org/cancerimmunolres/article-abstract/8/5/672/470110 Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential Q Zhao , M Ahmed, DV Tassev, A Hasan , TY Kuo - Leukemia, 2015 - nature.comhttps://www.nature.com/articles/leu2015125 Development of a T-cell receptor mimic antibody targeting a novel Wilms tumor 1-derived peptide and analysis of its specificity N Kurosawa, A Midorikawa, K Ida, YW Fudaba - Cancer , 2020 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1111/cas.14602 Generation and expression of high affinity, tumor antigen-specific mouse and human T cell receptors to genetically modify CD8 (+) T cells for adoptive ML Dossett - 2006 - search.proquest.comhttps://search.proquest.com/openview/e15a6c0fb38ba9554ef38793b6bb4bcb/1?pq-origsite=gscholar&cbl=18750&diss=y An input-controlled model system for identification of MHC bound peptides enabling laboratory comparisons of immunopeptidome experiments MG Klatt , ZEH Aretz , M Curcio, RS Gejman - Journal of , 2020 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S187439192030289X An essential role of the avidity of T-cell receptor in differentiation of self-antigen-reactive CD8+ T cells K Kondo, F Fujiki, H Nakajima - Journal of , 2016 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2016/04000/an_essential_role_of_the_avidity_of_t_cell.3.aspx Opposite effects of endogenous peptide-MHC class I on T cell activity in the presence and absence of CD8 JD Stone , DH Aggen , AS Chervin - The Journal of , 2011 - journals.aai.orghttps://journals.aai.org/jimmunol/article/186/9/5193/84974 Escherichia coli expressing recombinant WT1 protein and listeriolysin O stimulate antigen-specific T cells following vaccination in C57BL/6 mice. J Nitcheu, FS Ramirez-Jimenez, HJ Stauss, G Vassaux - 2004 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/104/11/4289/73464 Comprehensive mutagenesis identifies the peptide repertoire of a p53 T-cell receptor mimic antibody that displays no toxicity in mice transgenic for human HLA-A I Trenevska, AP Anderson, C Bentley, T Hassanali - Plos one, 2021 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0249967 High Avidity HLA-A2-Restricted CD8+ T Cells against the Wilms Tumor Protein (WT1) Can Be Isolated Only from HLA-A2 Negative Donors Not Subjected to HLA-A2 I Jedema, M van de Meent, WJJ Falkenburg - Blood, 2008 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006497119511855 A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer HG Rammensee , KH Wiesmuller, PA Chandran - for immunotherapy of , 2019 - Springerhttps://link.springer.com/article/10.1186/s40425-019-0796-5 Wilms tumor 1 protein is highly expressed on malignant plasma cells and provides a novel target for immunotherapeutic approaches G Koehne, S Kosuri, E Doubrovina, T Dao, A Scott - 2015 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/126/23/98/136288 Galinpepimut-S, a Wilms' tumor protein 1 (WT1)-targeting immuno-oncology treatment, induces specific, robust, and durable immune responses (IRs) in patients G Koehne, S Devlin , N Korde, S Mailankody , H Landau - researchgate.nethttps://www.researchgate.net/profile/Nicholas-Sarlis/publication/333699864_Galinpepimut-S_a_Wilms'_tumor_protein_1_WT1-targeting_immuno-oncology_treatment_induces_specific_robust_and_durable_immune_responses_IRs_in_patients_with_high-risk_HR_multiple_myeloma_MM/links/5cffb0184585157d15a2344b/Galinpepimut-S-a-Wilms-tumor-protein-1-WT1-targeting-immuno-oncology-treatment-induces-specific-robust-and-durable-immune-responses-IRs-in-patients-with-high-risk-HR-multiple-myeloma-MM.pdf The physiological interactome of TCR-like antibody therapeutics in human tissues E Marrer-Berger, A Nicastri, A Augustin - Nature , 2024 - nature.comhttps://www.nature.com/articles/s41467-024-47062-5 In Vivo Eradication of Human Clonigenic Acute Lymphoblastic Leukemic Cells Expressing the Wilms Tumor Protein, WT-1, by HLA Restricted WT-1 Specific T-Cells in E Doubrovina, M Doubrovin , E Kanaeva, RJ O'Reilly - Blood, 2007 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006497119868295 Generation and use of HLA-A2-restricted, peptide-specific monoclonal antibodies and chimeric antigen receptors DV Tassev - 2011 - mskcc.orghttps://www.mskcc.org/sites/default/files/node/165658/document/final-dimiter-tassev.pdf A Cytotoxic Human Monoclonal Antibody Recognizing Cell Surface WT1 Peptide/HLA-A2 Complexes DA Scheinberg, T Dao, S Yan, L Zhou, T Korontsvit - 2011 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/118/21/1677/139829 Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA CJ Holland, RM Crean , JM Pentier - The Journal of , 2020 - Am Soc Clin Investighttps://www.jci.org/articles/view/130562 Vaccination with the WT-1 126-134 Peptide in Patients with Acute Myeloid Leukemia after Allogenic Stem Cell Transplantation. C Gentilini, A Letsch , A Asemissen, A Muessig - Blood, 2006 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006497118451221 Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody C Augsberger , G Hanel, W Xu, V Pulko - Blood, The Journal , 2021 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/138/25/2655/476420 1 WITH AT CELL BISPECIFIC ANTIBODY (WT1-TCB): EX VIVO AND IN VIVO POTENCY BY BIVALENT RECOGNITION OF PEPTIDE-MHC COMPLEXES FROM AN C Augsberger , C Klein , C Heitmuller, W Xu - , 2019 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1097/01.HS9.0000559044.46812.aa Two to tango: engineered T cells against AML C Arber - Blood, 2024 - ashpublications.orghttps://ashpublications.org/blood/article/143/6/476/514777 Gemcitabine/WT1 peptide loaded dendritic cell vaccine A Soeda - Reactions, 2011 - Springerhttps://link.springer.com/article/10.2165/00128415-201113350-00080 INDUCTION OF IMMUNE RESPONSES TO WILMS TUMOR 1 (WT1), A SELF-ANTIGEN, IN MICE A Saint-Fleur - 2014 - jscholarship.library.jhu.eduhttps://jscholarship.library.jhu.edu/bitstream/1774.2/39279/1/SAINT-FLEUR-DISSERTATION-2014.pdf

Hinweis:
Unsere Produkte sind nur für Laborzwecke. Für jede andere Verwendung, bitte melden sie sich bei uns.
Marke:
Biosynth
Langzeitlagerung:
Hinweise:

Chemische Eigenschaften

MDL:
Schmelzpunkt:
Siedepunkt:
Flammpunkt:
Dichte:
Konzentration:
EINECS:
Merck:
HS-Code:

Gefahrenhinweise

UN-Nummer:
EQ:
Klasse:
H-Sätze:
P-Sätze:
Flugverbot:
Gefahrenhinweis:
Verpackungsgruppe:
LQ:

Technische Anfrage zu: 3D-PP49836 H-R^MFPNAPYL-OH

Bitte verwenden Sie stattdessen den Warenkorb, um ein Angebot oder eine Bestellung anzufordern

Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.

* Obligatorische felder
Willkommen bei CymitQuimica!Wir verwenden Cookies, um Ihren Besuch zu verbessern. Wir schließen Werbung nicht ein.

Bitte beachten Sie unsere Cookie-Richtlinie  für weitere Details oder passen Sie Ihre Einstellungen unter “Konfigurieren” an.